Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs – Zoetis

1. Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs  Zoetis
2. Long-acting drug for reducing canine OA pain receives European marketing authorization  DVM360
3. Zoetis receives European Commission marketing authorization for Lenivia (izenivetmab) to reduce pain associated with osteoarthritis (OA) in dogs  MarketScreener
4. Zoetis Receives European Commission Marketing Authorization for Lenivia  Business Wire

Continue Reading